RMTI earnings

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, May 7, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Officer Format: Discussi

Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. Generated 21% in gross margin for the fourth quarter 2025, representing one of the strongest quarters for gross margin in the Company's history and a meaningful improvement over 15% gross margin for the same period in 2024. Reported $2.3 million in cash flow from operating activities in the fourth quarter 2025, which increased the Company's cash position at year-end 2025 to $25.0 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufact

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, March 26, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Off

Net sales for the third quarter 2025 were $15.9 million. Company reiterates 2025 guidance for net sales to be between $65 million and $70 million. Achieved profitability on an Adjusted EBITDA basis for the third quarter 2025. Increased cash position to $23.7 million at September 30, 2025. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2025. "During the third quarter, we continued to right-size our organization to enhance ope

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2025 on Wednesday, November 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Wednesday, November 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMe

Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025. "During the second quarter of 2025, we successfully managed through the transition of our largest customer away from Rockwell Medical and now find ou

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Resu

Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, March 20, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMe

Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. Reports gross profit of $6.2 million for the third quarter of 2024, an increase of 183% over the same period in 2023. Achieves gross margin of 22% for the third quarter of 2024 compared to a gross margin of 9% for the same period in 2023. Generates $4.3 million in cash flow from operations for the third quarter of 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops

Due to the U.S. Securities and Exchange Commission (SEC) and its Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system being closed on Monday, November 11, 2024 in observance of Veteran's Day, the Company will release its financial and operational results for the Third Quarter 2024 on Tuesday, November 12, 2024 Press release will be issued at 6:00am ET followed by a live conference call and webcast at 8:00am ET Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has updated the date for its third quart

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, November 11, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Result

Reports net sales of $25.8 million for the second quarter of 2024, an increase of 43% over the same period in 2023. Reports gross profit of $4.6 million for the second quarter of 2024, an increase of 341% over the same period in 2023. Achieves gross margin of 18% for the second quarter of 2024 compared to a gross margin of 6% for the same period in 2023. Generates $1.4 million in cash flow from operations for the second quarter of 2024. Expects net sales for 2024 to range between $95 million and $98 million, raising guidance for the second time this year. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, a

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 8, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Result

Reports record net sales of $22.7 million for the first quarter of 2024, an increase of 25% over net product sales and a 15% increase over net sales for the same period in 2023. Reports record gross profit of $3.1 million for the first quarter of 2024, an increase of 18% over the same period in 2023. Raises guidance for net sales, gross profit, and profitability on an adjusted EBITDA basis for the full-year 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three mo

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2024 on Tuesday, May 14, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Tuesday, May 14, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Fo

Reports record net sales for second year in a row, generating $83.6 million in 2023, an increase of 15% over 2022. Net sales for the fourth quarter of 2023 were $22.1 million, an increase of 14% over the same period in 2022. Reports record net product sales for second year in a row, generating $79.8 million in 2023, an increase of 15% over 2022. Net product sales for the fourth quarter of 2023 were $22.1 million, an increase of 22% over the same period in 2022. Reports record gross profit for the second year in a row, generating $8.7 million in 2023, an increase of 114% over 2022. Achieves profitability on an adjusted EBITDA basis in the fourth quarter of 2023, the first time in t

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, March 21, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.Rock

Defers principal payments of $8.0 million up to three years, reduces Rockwell's need for additional operating capital, and enhances the Company's cash balance Rockwell Medical provides preliminary projected fourth quarter and full-year 2023 financial results Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company amended its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"). Rockwell Medical and its wholly owned subsidiary, Rockwell Transportation, Inc., initially e

Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. Gross profit for the third quarter of 2023 increased 183% over the same period in 2022. Gross margin for the third quarter of 2023 was 9%, an increase from 4% for the same period in 2022. Operating loss for the third quarter of 2023 was $1.7 million, a 41% improvement over the second quarter of 2023 and a 53% improvement over the same period in 2022. Rockwell Medical reiterates projected 2023 net sales to be between $82.0 million and $86.0 million, an increase of 17% to 18% year-over-year, and pro

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2023 on Tuesday, November 14, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Tuesday, November 14, 2023 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.co

Net sales for the six months ended June 30, 2023 was $37.7 million, an 8% increase over $34.8 million for the same period in 2022. Gross profit for the six months ended June 30, 2023 was $3.6 million, a 260% increase over $1.0 million for the same period in 2022. Gross margin for the six months ended June 30, 2023 was approximately 10%, a 233% increase over 3% for the same period in 2022. Subsequent to the second quarter of 2023, Rockwell Medical acquired a profitable and fully automated hemodialysis concentrates business from Evoqua Water Technologies. The acquisition significantly expands Rockwell Medical's geographic footprint, customer base, and product offerings. At the time of

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, August 14, 2023 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results

Adds profitable business that generates approximately $18 million in annual revenue and will add over $3.3 million in annual EBITDA for Rockwell Medical. Significantly expands Rockwell Medical's geographic footprint, customer base, and product offerings; Adds fully automated manufacturing know-how and capacity. Rockwell Medical increases its 2023 revenue guidance to between $82.0 million and $86.0 million. Conference call and webcast will be held today at 8:00am ET Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced

Achieved fourth consecutive quarter of revenue growth with new high of $19.7 million, representing a 22.4% increase over the same period in 2022 Achieved $2.6 million in gross profit, representing a 425% increase over the same period in 2022 Continued to reduce expenses and improve earnings per share with focus on driving enhanced business performance Entered into several new long-term supply, product purchase, and distribution agreements Reiterates 2023 guidance of revenue between $78.0 million and $82.0 million and gross profit between $7.0 million and $9.0 million Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, comme

Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2023 on Monday, May 15, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 15, 2023 Time: 8:00am ET Webcast: www.RockwellMed.com/Results Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Replay Number: (800) 770-2030 // (Internation

Rockwell Medical, Inc. (NASDAQ:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2022 on Thursday, March 30, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, March 30, 2023 Time: 8:00am ET Webcast: www.RockwellMed.com/Results Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Replay Number: (800) 770-2030

Rockwell is restructuring its business in the short-term to drive revenue and expansion opportunities in the growing hemodialysis market and through international pharmaceutical sales By making this strategic shift, Rockwell expects to achieve profitability in 2024, strengthen its overall financial position, and reduce the Company's reliance on the capital markets to fund future business growth Rockwell amended its long-term debt agreement to align with its updated strategic direction; Reduced debt from $15 million to $10 million Revenue was $18.7 million for the third quarter 2022, which represents the highest quarterly revenue to-date for Rockwell Cash used in operating activ

Rockwell Medical, Inc. (NASDAQ:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Please call 10 minutes prior to the call to register. Date: Monday, November 14, 2022 Time: 8:00am ET Webcast: www.RockwellMed.com/Results Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Repl

Revenue was $18.7 million for the second quarter 2022, a 16% increase over the first quarter 2022, representing the highest quarterly revenue to-date for Rockwell Gross profit was $1.7 million in the second quarter 2022 compared to gross loss of $786,000 in the first quarter 2022 Cash used in operating activities was $5.8 million for the second quarter 2022, a 40% decrease over the first quarter of 2022 Completed $30 million financing and stabilized the business Rockwell Medical, Inc. (NASDAQ:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced its fi

WIXOM, Mich. , Aug. 3, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.  CONFERENCE CALL AND WEBCAST DETAILSPlease call 10 minutes prior to the call to register. Date:

WIXOM, Mich., May 11, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 16 at 4:15 PM ET to discuss its financial results for the three months ended March 31, 2022, and recent operational highlights. To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time

- Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year -       - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion -                         - Company recently presented Triferic® real world evidence update at ASN Kidney Week 2021; results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis -   - Q3 2021 conference call and webcast scheduled for today at 4:00 p.m. ET - WIXOM, Mich.

WIXOM, Mich., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 15 at 4:00 PM ET to discuss its financial results for the three months ended September 30, 2021, and recent operational highlights. To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 7697945. A live webcast of the call will be available under "Events & P

-Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic® in Turkey- -Extended multi-year distribution agreement with Nipro Medical for dialysis concentrates in LATAM and the Caribbean- -Q2 2021 conference call and webcast scheduled for today at 4:30 p.m. ET- WIXOM, Mich., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended June 30, 20